2023 - Zeteo Tech

Zeteo Tech Awarded $1.87M DHS Science & Technology Directorate Contract to Develop and Test the Next Generation of the digitalMALDI® Real-Time Biological Threat Detection Technology

We are excited to share that the U.S. Department of Homeland Security has awarded Zeteo Tech a Phase III Small Business Innovation Research contract for $1.87M, with a potential value of up to $5.86 million. This new contract will fund the development and testing of digitalMALDI®, our next generation of sensor technology that enables real-time detection of aerosolized biological-threat agents that include bacteria, viruses, and toxins.

We look forward to assisting the DHS Science and Technology Directorate with its ongoing efforts to develop new tools for improving detection and response times to potential bioterrorism attacks or naturally occurring biological incidents.

Zeteo Tech Expands IP Portfolio of Mass Spectrometry Technology

SYKESVILLE, Md.–(BUSINESS WIRE)–Zeteo Tech, Inc., the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers and innovative human breath detection technologies, announced today the issuance of U.S. Patent No. 11658021, titled “Systems and Methods of Rapid and Autonomous Detection of Aerosol Particles.”

Using the patented “point-of-need” portable threat detection system, air samples can be automatically collected and analyzed for chemical and biological aerosolized threat agents, including bacteria, viruses, toxins, and chemicals such as fentanyl. The system’s sophisticated microfluidics, control architecture, threat agent library, and AI/ML software enable threat identification with high specificity and sensitivity within just a few minutes.

“This latest patent adds to Zeteo Tech’s robust IP portfolio protecting our technology that can perform rapid analysis of biological aerosols, including bacteria, viruses, and toxins,” said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “Our mission is to collaborate with partners to commercialize our technology in order to help protect life and critical infrastructure by enabling rapid detection and accelerated initiation of emergency management protocols. For example, the system is capable of rapidly detecting new biological threats and being deployed in potential pandemic scenarios, similar to COVID-19.”

This patent marks the fourth U.S. Patent for Zeteo Tech on mass spectrometry technology, (3 granted and 1 allowed). In addition, Zeteo Tech has 12 mass spectrometry related foreign patents, (11 granted and 1 allowed).

Zeteo Tech has licensed its portable threat detection technology to Albuquerque-based bioaerosol surveillance company, BioFlyte. This agreement allows BioFlyte to use the technology for environmental sampling, detection, monitoring, and identification of chemical and biological threats within the defense and security market. BioFlyte is partnering with financial institutions, government organizations, like the Department of Defense, and airports, such as the Pittsburgh International Airport, to test and demonstrate the capabilities of its BioTOF™ z200 system.

“BioFlyte emerged from Zeteo Tech’s impressive portfolio of proprietary mass spectrometry technology, and our ongoing strategic partnership has been critical for our growth,” said BioFlyte CEO Todd Sickles. “With Zeteo’s support, BioFlyte is commercializing this groundbreaking rapid threat detection technology to protect people, critical infrastructure, and more.”

To learn more about Zeteo Tech and its technology, please visit www.zeteotech.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Zeteo’s instruments identify airborne microbes, proteins, and lipids, and can be used to screen for infectious disease and other biothreats. Its innovative, patented and patent-pending time of flight mass spectrometry technology, digitalMALDI^®, enables fully automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being currently deployed for biodefense applications. To learn more, visit www.zeteotech.com.

Contacts

Media
Brandon Reid for Zeteo Tech
bwr@anzupartners.com

https://www.businesswire.com/news/home/20231114380747/en/Zeteo-Tech-Expands-IP-Portfolio-of-Mass-Spectrometry-Technology

Zeteo Tech Awarded Competitive Grant From the National Institute of Allergy and Infectious Diseases

Small Business Innovation Research Program provides seed funding to fuel R&D for Zeteo
Tech’s Innovative Approach for Detecting Disease Markers in Human Breath.

Zeteo Tech, Inc. the biodefense and medical device company that has developed a
revolutionary new class of fieldable biological mass spectrometers and innovative human breath
detection technologies, has been awarded a National Institute Of Allergy And Infectious
Diseases (NIAID) Direct to Phase II Small Business Innovation Research (SBIR) grant for
$967,498, for the first year of a two year effort, totaling $1.9M, on “Noninvasive Diagnostic
Markers of Lower Respiratory Tract Infection in Mechanically Ventilated Patients”. Dr. Dapeng
Chen of Zeteo Tech, Inc. is the Principal Investigator for this grant.

The potential for human breath to serve as a non-invasive diagnostic tool has garnered
significant attention from healthcare professionals and industry experts alike. Lower respiratory
tract infections (LRTIs) are a common concern for ICU patients, particularly those with
mechanical ventilators. Zeteo Tech, Inc., in collaboration with the Johns Hopkins Hospital, will
investigate whether truncated proteoforms in human exhaled air can serve as a non-invasive
diagnostic marker for LRTIs, and early prediction of LRTI in mechanically ventilated patients. If
successful, this breakthrough research will provide clinicians with a valuable tool for decision-making
regarding antibiotic treatment, resulting in improved patient outcomes and reduced exposure to harmful
antibiotic treatments.

“We are absolutely delighted to win this highly competitive award from NIAID for our research
directed toward breath-based detection and characterization of LRTI. Dr. Chen, his team at
Zeteo Tech, and collaborators from Johns Hopkins developed highly convincing evidence for
this approach, leading to this NIAID award, and we are pleased to now add ASELL, LLC to the
team to support our commercialization efforts. This work is a critical component in Zeteo Tech’s
drive to transition technology investments by the Department of Defense and Department of
Homeland Security into medical tools that will revolutionize the diagnosis and treatment of lung
infections. Beyond LRTI, we expect these tools to evolve into platforms for point-of-care
diagnosis and assessment of multiple disease states and conditions.” said Wayne Bryden,
President and CEO of Zeteo Tech, Inc.

The work in this press release is supported by the National Institute Of Allergy And Infectious Diseases of the
National Institutes of Health under Award Number R44AI177245. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the National Institutes of Health